Priya Singhal News Today

BOSTON, MA / ACCESSWIRE / May 23, 2024 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of discussion and networking at its annual Longwood

Biogen has agreed to pay at least $1.15 billion for biotech firm Human Immunology Biosciences as it moves to increase its immunology portfolio.

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational

HI-Bio is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications.

The deal comes as the Cambridge drugmaker seeks to bolster its pipeline of experimental medicines.

Clearbridge Investments LLC cut its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 7.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,679,302 shares of the biotechnology company’s stock after selling 143,880 shares during the quarter. Clearbridge Investments LLC owned approximately 1.16% of […]

Saratoga Research & Investment Management decreased its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,226 shares of the biotechnology company’s stock after selling 11,838 shares during the period. […]

BNP Paribas Asset Management Holding S.A. trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 32.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 448,432 shares of the biotechnology company’s stock after selling 212,114 shares during the period. BNP Paribas Asset […]

Independent Advisor Alliance increased its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 4.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,051 shares of the biotechnology company’s stock after purchasing an additional 363 shares during […]